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The therapeutic value of donor lymphocyte infusions
(DLI) in patients who relapse with AML is limited by a
low efficacy and a high risk of GVHD. Therefore, we aim
at generating leukemia reactive donor T cells for patients
with AML. So far, 4 patient-donor pairs were evaluated
(Table 1). Donor PBMC were stimulated with mature
donor dendritic cells (DC), pulsed with irradiated and
anti-CD34 MAb coated patient leukemic blasts (LB), or
directly with cytokine (GM-CSF, IL-4, TNFalpha) treated
LB. A 2–3-fold expansion of donor T cells occured in all
experiments. Immunophenotyping showed a predomi-
nant outgrowth of CD4+ cells (80–95% of CD3+ cells) in
all but one patient (75% CD8), with 0–1% CD56+/CD3-
cells. After three weekly stimulations, donor cells were
tested for IFNgamma secretion by ELISPOT assay after
stimulation with irradiated leukemic blasts cells (LB) and
non-leukemic controls, depending on the availability of
patient cells. In 4/5 donors, cells with reactivity against
patient LB with low or no reactivity against patient non-
leukemic cells could be generated. In the remaining
patient, the resulting donor T cell line showed a higher
IFNgamma secretion after stimulation with patient PHA
blasts than LB, but none after stimulation with third party
LB. Direct stimulation with cytokine treated LB was per-
formed in one donor (04), resulting in reactivity against
LB and not PHA blasts, but high reactivity against 3rd party
EBV-transformed B cells (LCL). In one patient so far (02),
leukemia reactive donor T cells were expanded with a
recently developed system using gene-modified K562 cells
loaded with anti-CD3 and anti-CD28 antibodies [1,2].
One week of expansion resulted in a 10-fold increase of
reactivity with sustained specificity of the resulting T cell
line (not shown). Characterisation of tumor reactive
donor T cells by MHC blocking experiments in one donor
(02) and separate analysis of T cell subsets in a second
donor (04) indicated that specific anti-leukemic reactivity
was mainly mediated by CD4+ T cells in those donors.
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Table 1: 
Targets
Donors Leukemic blasts PHA- T cell blasts CD34 neg. cells EBV- B cells 3rd party leukemic blasts
1 252 77 21
2 11 ± 0 2 ± 1
4 33 ± 1 4 ± 2
7 70 113 16
10 36 ± 4 7 ± 0
Numbers shown are spots/1e5 effector cells (IFNgamma ELISPOT) ± std errPage 1 of 2
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